Overview

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Status:
Recruiting
Trial end date:
2026-01-03
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Afatinib
Atezolizumab
Bevacizumab
Carboplatin
Docetaxel
Everolimus
Loperamide
Palbociclib
Panitumumab
Pembrolizumab
Pemetrexed
Trametinib